Opana ER 10mg is indicated for the relief of moderate to severe pain and also as a preoperative medication to alleviate apprehension, maintain anaesthesia and as an obstetric analgesic. It can be used to alleviate pain in dyspnea associated with acute left ventricular failure and pulmonary edema. It has practically no cough suppressing activity.Pill with imprint 10 is Yellow, Eight-sided and has been identified as Opana ER 10 mg.
Opana ER 10mg extended-release tablets are indicated for the management of chronic pain and only for people already on a regular schedule of strong opioids for a prolonged period. Immediate-release Opana ER 10mg tablets are recommended for breakthrough pain for people on the extended-release version.
The principal adverse effects of Opana ER 10mg are similar to other opioids with constipation, nausea, vomiting, dizziness, dry mouth and drowsiness being the most common adverse effects. This drug is highly addictive as with other opioids and can lead to chemical dependence and withdrawal.
In common with other opioids, oxymorphone overdosage is characterized by respiratory depression, sleepiness progressing to stupor or coma, skeletal muscle weakness, cold and clammy skin, and sometimes slow heart rate and low blood pressure. In a severe case of overdose, apnea, circulatory collapse, cardiac arrest and death can occur.
It elicits its effects by binding to and activating the mu opioid receptor (MOR) and, to a lesser extent, the delta opioid receptor (DOR). Its activity at the DOR likely augments its action at the MOR. Oxymorphone is 10 times more potent than morphine